Medivir Ab

Janssen R&d Ireland

Tibotec Pharmaceuticals Ltd.

Janssen Sciences Ireland Uc

Tibotec Bvba

Medivar Ab

Astra Pharmaceutical Production Aktiebolag

Tibotec Pharmaceuticals Ltd. Co

Medivir Aktiebolag

Bengt Bertil Samuelsson

Åsa Annica Kristina Rosenquist

Kenneth Simmen

Karl Magnus Nilsson

Pierre Jean-Marie Bernard Raboisson

Herman Augustinus De Kock

Lili Hu

Abdellah Tahri

Dominique Louis Nestor Ghislain Surleraux

Sandrine Marie Helene Vendeville

Per-Ola Mikael Johansson

Vladimir Kirillovich Ivanov

Mikael Pelcman

Bjorn Olof Classon

Ingemar Sven-Anders Kvarnstrom

Hans Kristian Wallberg

Dmitry Antonov

Anna Karin Gertrud Linnea Belfrage

Stefan Carl Svensson

Lars Goran Svansson

Carl Erik Daniel Jönsson

Anna Karin Gertrud Linea Belfrage

Pia Kahnberg

Lourdes Salvador Odén

Björn Olof Classon

Susana Ayesa Alvarez

David Craig McGowan

Bart Rudolf Romanie Kesteleyn

Wim Van De Vreken

David Craig Mc Gowan

Bjorn Olaf Classon

Mats Stefan Lindström

Genadiy Kalayanov

Wim Bert Griet Schepens

Kevin Parkes

Johannes Wilhelmus J Thuring

Pierre Jean-Marie Bernard Rabiosson

Jörg Kurt Wegner

Horst Jürgen Wähling

Karin Charlotta Lindquist

Ismet Dorange

Vladimir Ivanov

Imgemar S Kvarnstrom

Bo A Lindqvist

Britt I Keding

Anna Karin Belfrage

Karl Magnus Milsson

Susana Ayesa Alverez

Herman Agustinus De Kock

Sven Crister Sahlberg

Yvan Simonnet

Michael Pelcman

Kenneth Alan Simmen

Joerg Kurt Wegner

Horst Jürgen WÄHLING

ÅSa Annica Kristina Rosenquist

Pia Cecilia Kahnberg

Åsa Annica Kristina Rosenquist

Inhibitors of HCV replication of formula (I) 

Macrocyclic inhibitors of hepatitis C virus

Inhibitors of HCV replication of formula (I) and the N-oxides, salts, and stereoisomers, wherein

Inhibitors of HCV replication of formula (I) and the N-oxides, salts, and stereoisomers, wherein each dashed line represents an optional double bond;

Inhibitors of HCV replication of formula (I) and the N-oxides, salts, or stereoisomers thereof, wherein the dashed line, X, R, R, R, R, R, R, and Rhave defined meanings; the preparation thereof; compositions containing compounds of formula (I), including bioavailable combinations with ritonavir; and the pharmaceutical uses thereof.

Inhibitors of HCV replication of formula (I) the N-oxides, salts, and stereochemically isomeric forms thereof, wherein each dashed line (represented by) represents an optional double bond;

HIV inhibitors of formula (I) wherein Ris halo, Calkoxy, trifluoromethoxy; Ris a group of formula (A); Ris a group of formula (B); Ris a group of formula (C); n is 0 or 1; A is CH or N; Rand Rare hydrogen, Callyl, halo; Rand Rare Callyl or Calkoxy-Calkyl; Ris Callyl, cyclopropyl, trifluoromethyl, Calkoxy, or dimethylamino; Ris hydrogen, Calkyl, cyclopropyl, trifluoromethyl, Calkoxy, or dimethylamino; pharmaceutically acceptable addition salts and solvates thereof; pharmaceutical compositions containing these compounds as active ingredient and processes for preparing said compounds.

5-amino-4-hydroxypentoyl amides

Compounds of the formula I: including a stereoisomer thereof, or an N-oxide, a pharmaceutically acceptable addition salt, or a pharmaceutically acceptable addition solvate thereof; useful as HCV inhibitors; processes for preparing these compounds as well as pharmaceutical compositions comprising these compounds as active ingredient.

HCV inhibiting macrocyclic phenylcarbamates

Macrocylic inhibitors of hepatitis C virus

Macrocylic compounds having inhibitory activity on the replication of the hepatitis C virus (HCV) of the general formula (I) 

Inhibitors of HCV replication of formula (I) and the N-oxides, salts, and stereoisomers thereof, wherein each variable has specific definitions. Pharmaceutical compositions containing compounds (I) and process for preparing compounds (I) are also provided. Bioavailable combinations of the inhibitors of HCV of Formula (I) with ritonavir are also provided.

Inhibitors of HCV of formula (I). and the N-oxides, salts, and stereoisomers thereof, wherein the dashed line represents an optional double bond between atoms C7 and C8; Ris hydrogen or Calkyl; Ris hydrogen or Calkyl; and n is 3, 4, 5, or 6;pharmaceutical compositions containing compounds (I) and processes for preparing compounds (I) are provided. Bioavailable combinations of the inhibitors of HCV of formula (I) with ritonavir are also provided.

Growing community of inventors

Skarholmen, Sweden

Bengt Bertil Samuelsson